If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Vittorio Montefusco is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 34 Similar Profiles
Multiple Myeloma Medicine & Life Sciences
Stem Cell Transplantation Medicine & Life Sciences
Thalidomide Medicine & Life Sciences
Cyclophosphamide Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences
Prednisone Medicine & Life Sciences
Maintenance Medicine & Life Sciences
Melphalan Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1997 2019

  • 2632 Citations
  • 25 h-Index
  • 98 Article
  • 4 Review article
  • 2 Conference contribution
  • 1 Comment/debate

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials

Larocca, A., Mina, R., Offidani, M., Liberati, A. M., Ledda, A., Patriarca, F., Evangelista, A., Spada, S., Benevolo, G., Oddolo, D., Innao, V., Cangialosi, C., Bernardini, A., Musto, P., Amico, V., Fraticelli, V., Paris, L., Giuliani, N., Falcone, A. P., Zambello, R. & 7 others, De Paoli, L., Romano, A., Palumbo, A., Montefusco, V., Hajek, R., Boccadoro, M. & Bringhen, S., Jun 27 2019, In : Haematologica.

Research output: Contribution to journalArticle

Multiple Myeloma

Ocular disorders in multiple myeloma patients: cross-sectional study of prevalence and association with treatment

Pennisi, M., Berchicci, L., Miserocchi, E., Mussetti, A., Cacioppo, V., David, A., Scialdone, A., Lorusso, I., Modorati, G., Corradini, P. & Montefusco, V., Jan 28 2019, In : Leukemia and Lymphoma. 60, 2, p. 477-482 6 p.

Research output: Contribution to journalArticle

Multiple Myeloma
Cross-Sectional Studies
Dry Eye Syndromes
3 Citations (Scopus)

Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: A pooled analysis of two phase i/ii studies

Bringhen, S., Mina, R., Petrucci, M. T., Gaidano, G., Ballanti, S., Musto, P., Offidani, M., Spada, S., Benevolo, G., Ponticelli, E., Galieni, P., Cavo, M., Di Toritto, T. C., Di Raimondo, F., Montefusco, V., Palumbo, A., Boccadoro, M. & Larocca, A., Jul 31 2019, In : Haematologica. 104, 8, p. 1640-1647 8 p.

Research output: Contribution to journalArticle

Multiple Myeloma
Disease-Free Survival

Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs

Montefusco, V., Gay, F., Spada, S., De Paoli, L., Di Raimondo, F., Ribolla, R., Musolino, C., Patriarca, F., Musto, P., Galieni, P., Ballanti, S., Nozzoli, C., Cascavilla, N., Ben-Yehuda, D., Nagler, A., Hajek, R., Offidani, M., Liberati, A. M., Sonneveld, P., Cavo, M. & 2 others, Corradini, P. & Boccadoro, M., Jun 20 2019, In : Haematologica.

Research output: Contribution to journalArticle

Multiple Myeloma
Pharmaceutical Preparations
Disease-Free Survival
Proteasome Inhibitors
Multivariate Analysis

PD-L1, LAG3, and HLA-DR are increasingly expressed during smoldering myeloma progression

Mussetti, A., Pellegrinelli, A., Cieri, N., Garzone, G., Dominoni, F., Cabras, A. & Montefusco, V., Jul 1 2019, In : Annals of Hematology. 98, 7, p. 1713-1720 8 p.

Research output: Contribution to journalArticle

HLA-DR Antigens
Multiple Myeloma
Plasma Cells
Cellular Microenvironment
Plasma Cell Neoplasms